一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

返回ChemicalBook首頁>CAS數(shù)據(jù)庫列表>769169-27-9

769169-27-9

中文名稱 BEGACESTAT
英文名稱 Begacestat
CAS 769169-27-9
分子式 C9H8ClF6NO3S2
分子量 391.74
MOL 文件 769169-27-9.mol
更新日期 2026/06/02 09:48:14
769169-27-9 結(jié)構(gòu)式 769169-27-9 結(jié)構(gòu)式

基本信息

中文別名
5-氯-N-[(1S)-3,3,3-三氟-1-(羥基甲基)-2-(三氟甲基)丙基]-2-噻吩磺酰胺
英文別名
GSI-953
Begacestat
Begacestat(GSI-953)
GSI-953 DISCONTINUED
Begacestat (Synonyms: GSI-953)
5-Chloro-N-[(1S)-3,3,3-trifluoro-1-(hydroxyMethyl)-2-(trifluoroMethyl)propyl]-2-thiophenesulfonaMide
2-Thiophenesulfonamide, 5-chloro-N-[(1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]-
5-Chloro-N-[(1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2- (trifluoromethyl)propyl] thiophene-2-sulfonamide
(2S)-S-(5-chlorothiophen-2-yl)-4,4,4-trifluoro-1-hydroxy-N-Methyl-3-(trifluoroMethyl)butane-2-sulfonaMido

物理化學(xué)性質(zhì)

熔點(diǎn)153-155°C
沸點(diǎn)355℃
密度1.642
閃點(diǎn)169℃
儲(chǔ)存條件2-8°C
溶解度在DMSO中的溶解度≥15mg/mL
酸度系數(shù)(pKa)8.16±0.50(Predicted)
形態(tài)粉末
顏色白色至棕褐色
InChI1S/C9H8ClF6NO3S2/c10-5-1-2-6(21-5)22(19,20)17-4(3-18)7(8(11,12)13)9(14,15)16/h1-2,4,7,17-18H,3H2/t4-/m1/s1
InChIKeyPSXOKXJMVRSARX-SCSAIBSYSA-N
SMILESOC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F

安全數(shù)據(jù)

WGK Germany3
存儲(chǔ)類別11 - Combustible Solids
BEGACESTAT價(jià)格(試劑級(jí))
報(bào)價(jià)日期產(chǎn)品編號(hào)產(chǎn)品名稱CAS號(hào)包裝價(jià)格
2025/12/22HY-14175BEGACESTAT
Begacestat
769169-27-91mg800元
2025/12/22HY-14175BEGACESTAT
Begacestat
769169-27-910mM * 1mLin DMSO1100元
2025/12/22HY-14175Begacestat769169-27-95 mg1280元

常見問題列表

生物活性
Begacestat (GSI-953) 是淀粉樣前體蛋白 γ 分泌酶 (gamma-secretase) 的選擇性噻吩磺酰胺抑制劑 (IC50Aβ40=15 nM),有潛力用于阿爾茲海默癥的研究。
靶點(diǎn)

IC50: 15 nM (Aβ 40 ).

體內(nèi)研究

Begacestat (5 mg/kg, p.o. in mice) treatment for 4 h significantly reduces the Aβ 40 and Aβ 42 in brain (37% lowering of brain Aβ 40 and 25% lowering of Aβ 40 observed).
Begacestat (GSI-953: 0, 2.5, 5, or 10 mg/kg, oral gavage, 3 h) results in a dose-dependent reversal of contextual fear conditioning deficits when compound is orally administered 3 h before training. Significant deficits are observed after treatment with 2.5 mg/kg Begacestat, and there is some reversal of this at 5 mg/kg and full reversal at 10 mg/kg compared with vehicle-dosed Tg2576 mice.
A dosage-related trend of slightly lower percentages of SP CD4+ cells in males at all dosages (SP CD4+ cells=~11% in controls compared with ~7% to ~9% in Begacestat-dosed animals) and females at 2000 mg/kg/day (SP CD4+ cells=~10% in controls compared with ~8% in Begacestat-dosed animals) is observed.

Animal Model: Tg2576 mice
Dosage: 0, 2.5, 5, or 10 mg/kg
Administration: Oral gavage for two consecutive days
Result: Resulted in a dose-dependent reversal of contextual fear conditioning deficits when compound is orally administered 3 h before training.
Animal Model: Sprague-Dawley rats
Dosage: 0, 200, 600, or 2000 mg/kg/day for 10 (5 males/group and 5 females at 600 mg/kg/day) or 28 (10/sex/group) consecutive days
Administration: P.O. for 10 (5 males/group and 5 females at 600 mg/kg/day) or 28 (10/sex/group) consecutive days.
Result: A dosage-related trend of slightly lower percentages of SP CD4+ cells in males at all dosages and females at 2000 mg/kg/day was observed.
"769169-27-9" 相關(guān)產(chǎn)品信息
蒲城县| 周至县| 社会| 建水县| 买车| 庄浪县| 西乡县| SHOW| 遵义县| 南丹县| 延津县| 达州市| 安泽县| 高雄县| 名山县| 应城市| 麦盖提县| 蓬安县| 鄂伦春自治旗| 永春县| 屯留县| 潜山县| 丰城市| 南岸区| 象州县| 伽师县| 吉木萨尔县| 永胜县| 教育| 正定县| 兴和县| 建昌县| 柳河县| 如东县| 巨鹿县| 滦南县| 佛坪县| 开封市| 榆树市| 绥中县| 东乌|